Estimated reading time: 2 minutes
A newly discovered compound has exhibited the ability to reverse four types of chronic pain in animal studies. This was according to research conducted by NYU College of Dentistry’s Pain Research Center. They identified the pain management compound after screening 27 million candidates in the search for potential new drugs.
The compound, which indirectly regulates calcium channels by binding to an inner region, outperformed gabapentin without the accompanying side effects. Calcium channels are integral to pain signaling and are linked to the release of neurotransmitters. The compound, named CBD3063, emerged as a promising candidate for the treatment of pain. It was effective in mouse models for various types of pain, including injury-related, chemotherapy-induced neuropathy, inflammatory pain, and trigeminal nerve pain. Unlike gabapentin, CBD3063 did not induce side effects, making it an appealing option for future clinical trials in the quest for safer and more effective pain management.
Pain medicine research can enhance the quality of life for millions suffering from chronic pain. It plays a crucial role in understanding the mechanisms of pain, enabling the development of more effective and safer treatments. By identifying innovative compounds, like CBD3063, that can alleviate pain without debilitating side effects, research offers hope for patients seeking relief.
In the fight against chronic pain, PatientsLikeMe is proud to offer resources and community support to members. For more information about pain management, be sure to visit PatientsLikeMe today to create a free account!